Skip to main content

Advertisement

Cancer patients’ use of complementary and alternative medicine in Sweden: a cross-sectional study

Article metrics

Abstract

Background

Access to and advice on Complementary and Alternative Medicine (CAM) are uncommon within Swedish conventional cancer care and little is known about cancer patients’ own use of CAM. The aim of this cross-sectional study was to explore Swedish cancer patients´ patterns of CAM use, their experiences and preferences.

Methods

Questionnaires were distributed consecutively to 1297 cancer patients at a university hospital’s out-patient oncology units. The response rate was 58% (n = 755). Descriptive statistics were used to analyze the survey data. A logistic regression model was used to investigate the association between CAM use and gender, age and level of education. Open-ended responses were analyzed, using qualitative content analysis.

Results

Lifetime CAM use was reported by 34% (n = 256), and 26% (n = 198) used CAM after cancer diagnosis. Being female, younger and having higher education predicted CAM use. Most commonly used methods were natural products including vitamins and minerals and relaxation. Main reasons for CAM use were improvement of physical, general and emotional wellbeing and increasing the body’s ability to fight cancer. Satisfaction with CAM usage was generally high. Reported adverse effects were few and mild; 54% of users spent < 50 Euro a month on CAM. One third had discussed their CAM use with cancer care providers. More than half of all participants thought that cancer care providers should be able to discuss (58%) and to consider (54%) use of CAM modalities in cancer care.

Conclusions

Despite limited access and advice within conventional cancer care, one fourth of Swedish cancer patients use CAM. The insufficient patient-provider dialogue diverges with most patients’ wish for professional guidance in their decisions and integration of CAM modalities in conventional cancer care. Concurrent and multimodal CAM use implies challenges and possibilities for cancer care that need to be considered.

Background

Complementary and Alternative Medicine (CAM) is a broad set of non-mainstream practices including use of natural products, mind-body therapies and entire medical systems [1]. Use among cancer patients has increased in the last decades [2]. National and regional heterogeneity, gender, age, education and type of tumor appear to influence usage patterns and frequency [2,3,4]. Research on both effectiveness and risks of specific CAM modalities for cancer patients accumulates [5] and attempts to establish evidence-based clinical guidelines are made [6] and have recently been endorsed by the American Society of Clinical Oncology [7]. Open communication between patients and cancer care providers (beneath referred to as providers) has been valued essential to meet patients´ needs and to improve understanding regarding direct risks as well as to prevent indirect risks [8]. The authors of several studies [9,10,11,12] highlight the need of an improved dialogue concerning CAM. Leading comprehensive cancer centers [13] provide the concept of integrative oncology [14] as a patient-centered health care model to meet patients’ preferences, to ensure their safety and to optimize clinical outcomes [15,16,17,18]. Other authorities have established research centers and scientific information services about CAM [1, 19].

Previous studies on Swedish cancer patients’ CAM use have mainly focused on natural products [20] and specific groups of patients [10, 20] and indicate similar usage frequency as other high-income countries. Research on Swedish professionals´ perceptions of CAM indicate uncertainty about evidence, indications, contraindications and skepticism about high costs [21,22,23] .

Practice of evidence-based medicine requires integrating individual clinical expertise, patient values and circumstances with the best available external clinical evidence from systematic research [24]. To understand patient values and circumstances in relation to CAM it is crucial to study usage across different countries and cultures. This cross-sectional study builds on previous surveys to advance the view of cancer patients’ CAM use in general, focusing on Swedish cancer patients’ experiences and preferences.

Methods

Participants and inclusion

Data were collected from the three Oncological out-patient units (Fig. 1) at the Karolinska University Hospital, Stockholm with 14,614 patients during 2014 covering the region of Stockholm with 2.3 million of 10 million inhabitants in Sweden.

Fig. 1
figure1

Flow chart of data inclusion

Inclusion criteria for study participants were re-visits to oncologist or nurse implying active oncological treatment (radiotherapy, chemotherapy and other medical cancer therapies) or follow-up; curative or palliative stage of the disease; solid tumor (breast cancer, gynecological - urogenital –, or gastrointestinal cancer, head-neck cancer, lung cancer, skin cancer, thyroid cancer, sarcoma, tumors with unknown primary or brain tumor). Exclusion criteria were first-time visits since we wanted to explore CAM use after cancer diagnosis, and treatment visits for chemotherapy and radiotherapy in order to avoid duplicate answers.

Data collection

The study employed a cross-sectional design. Participants were asked to fill in a questionnaire with 19 questions including yes/no and multiple-choice responses as well as free text options (Table 1).

Table 1 Measures derived from data collection with questionnaire

Questionnaire content

The questionnaire previously used by Molassiotis et al. [3] was translated to Swedish and further adapted by the research team to suit the purpose of the present study and the local context. We excluded 8 items on background questions (income, ethnic group, religious beliefs and previous cancer treatment), 2 items regarding frequency of CAM use and 4 items concerning sick-leave, hospitalization and other health care visits. Moreover, 6 items on CAM use were merged into 1 item. The questionnaire ultimately contained 19 questions on demography, CAM use, reasons, used methods and details on experiences of and views on CAM (Table 1). An additional file shows the questionnaire in detail (Additional file 1).

Data collection procedures

During one week (September 2014), all patients with appointments for cancer treatment or follow-up were informed verbally by the receptionist at all three out-patient clinics (written information about the study, voluntary participation and confidentiality). Patients willing to participate, completed the anonymous questionnaire in the waiting room and left it into a designated post box. There was no opportunity offered to complete the questionnaire at home.

Statistics and data analysis

Data was summarized by descriptive statistics (frequencies and percentages). To investigate factors possibly associated with CAM use, Spearman correlation coefficients were calculated for CAM use versus gender, age and level of education and possible associations between these variables were explored with a logistic regression model. All calculations were done in STATA®.

Participants’ free-text responses were analyzed descriptively question-by-question according to principles of qualitative manifest content analysis by two researchers (KW and JHN) independently [25, 26]. The length of the free-text responses varied from one word to a few sentences. After reading all responses and compiling them into meaning units, the two researchers agreed upon a coding scheme for each response section. The codes within each section were then compared and contrasted and sorted into categories. The categories including example statements representing each category are presented in Table 2. These results were used for better understanding of quantitative data and as control whether there were missing options in the multiple-choice questions.

Table 2 Categorization of free-text responses with example statements

Measures

Participants´ characteristics and CAM use were assessed by question (Q) 1–8, adverse effects by Q11, dialogue about CAM and sources of information by Q15, 16 and 18; reasons for CAM use, perceived benefits, satisfaction and monthly costs by Q9, 10, 12–14 and the role of cancer care in relation to CAM by Q17 and 19 (see Table 1).

Results

Participants´ characteristics and CAM use

Out of 1297 eligible patients, 58% (n = 755) returned the questionnaires. Content and response options are shown in Table 1, patient characteristics in Table 3.

Table 3 Patient characteristics

We found no statistically significant gender difference between eligible patients (65% women, 35% men) and participants (64% women, 34% men, 2% unknown).

Use of CAM over lifetime was reported by 34% (n = 256) of the participants and 26% (n = 198) had used CAM after their cancer diagnosis (beneath referred to as CAM users). Onset of CAM use was specified by 77/198 CAM users; the majority stated either a time correlation to cancer diagnosis or to cancer treatment. We found that 31 different CAM modalities were used by 198 patients after cancer diagnosis. Most frequently used CAM modalities were vitamins and minerals, natural products and relaxation (Table 4). Each modality may in itself represent many different variations, such as different types of mindfulness or yoga. “Vitamins and minerals” for example, implied usage of 22 different substances and the option “natural products” 32 different products.

Table 4 Distribution of used CAM modalities. Categories according to National Center for Complementary and Integrative Health [1]

We found statistically significant correlations between use of CAM and being female (rs = 0.22, P < 0.01), younger (rs = 0.25, P < 0.01) and having a higher education (rs = 0.14, P < 0.01). This was confirmed by logistic regression model with gender, age and level of education as predictors and usage of CAM as a dependent variable (p < 0.01). The model explains the variation of CAM users vs. No CAM users with 6%.

Adverse effects

A total of 5.6% (n = 9) CAM users reported 11 adverse effects related to a CAM modality. Five reports related to gastrointestinal symptoms from mung bean sprout juice, iron, apricot pits, low-carb-high-fat diet during chemotherapy and one unknown remedy, respectively. Fever and shivering were reported from mistletoe, cough and morning fatigue from cannabis and pain from acupuncture needles. Two reports regarded undesirable effects of more reflective character, since detoxification from spirulina and possible toxification from intake of pesticides via fruits and vegetables was mentioned as adverse effects without reference to concrete symptoms. Finally, one report concerned an x-ray finding of a kidney stone and a reflection on overconsumption of spinach as possible cause.

Dialogue about CAM and sources of information

Among CAM users, 33% (n = 66/198) had discussed CAM with their physician or nurse compared with 2% (n = 13/557) among No CAM users.

Responses regarding the providers’ (physician or nurse) reactions to CAM related questions, ranged from approval or advice that CAM use was one’s own responsibility to recommendation to refrain use. A general concern among participants was that they thought providers ought to be more open and knowledgeable about CAM (see Table 2 Q15b). One participant stated: “There is research in the rest of the western world that is genuine /…/ Swedish doctors/nurses would benefit from being open to alternatives.”. Participants´ main reasons for not discussing CAM with their providers included expectation of negative attitudes, lack of time or continuity, absence of reason to bring up the topic and simply because “Nobody asked”.

The most common sources of information about CAM among both CAM users and No CAM users were media (n = 214), family or friends (n = 154) and internet (n = 118). CAM therapists were less common as information sources (n = 35) and conventional care least common (n = 26). Other sources (n = 63) involved own experiences and interests, literature, lectures, courses, patient organizations and other therapists.

Most patients reported that they preferred receiving information on CAM during personal counselling with a skilled person (n = 354). Written information, e.g. webpages or patient brochures (n = 245) and lectures (n = 93) were other options, while relatively few (n = 42) wanted to chat online.

Reasons for CAM use, perceived benefits, satisfaction and monthly costs

The most commonly reported reasons for CAM use were to improve physical and general well-being (Fig. 2). The majority of free-text responses were specifications of the pre-listed options in the multiple-choice question (see Table 2 Q9). For example, one woman specified: “To counteract strong hot flushes.” Only one response could be attributed to a reason for CAM use beyond the given options, i.e. because of declining conventional oncological treatment.

Fig. 2
figure2

Reasons for CAM use among CAM using cancer patients. Quantity of answers per reason. * “other reasons” from free text option (see Table 2 Q9)

The explanations given not to use CAM were mainly satisfaction with received conventional cancer care, never having thought about CAM use or disbelieve in methods lacking scientific prove. Less frequent reported reasons were economy or discouraging advice from friends, family or cancer care.

Perceived benefits of CAM were mainly improved physical and emotional well-being (Fig. 3). The free-text responses related to perceived benefits did not diverge from the pre-listed options but were rather specifications of experiences in relation to CAM use, perceived effects or lack of effects, and thoughts regarding the difficulty of evaluating effect (see Table 2 Q10). For example, one woman stated: “Have experienced many side-effects from the antioestrogen treatment but my sexual life has not been affected, my mucous membranes are not dry. Because of the primrose oil? Not of any use: The acupuncture that even hurt sometimes.”.

Fig. 3
figure3

Perceived benefits of CAM. Quantity of answers per benefit. * “Other effects” from free text option (see Tableb 2 Q10)

Most participants (87%, n=113) who reported their grade of satisfaction (n = 130) were very (45%, n = 58) or quite (42%, n = 55) satisfied with their CAM use; 12% (n = 15) were a bit satisfied and 2% (n = 2) not satisfied at all. More than half of the patients reported spending ≤50 € monthly while 3% spent > 500 €. Over 90% of the patients reported that they considered their CAM therapies worth the cost (Table 5). In the free text responses related to expenses, several patients highlighted the value of CAM for life in general (see Table 2, Q13). One participant wrote: “I got a new life. Even if I would die tomorrow, it would have been worth it”.

Table 5 Monthly costs for CAM and reported value

The role of cancer care in relation to CAM

Over two thirds of the CAM users and nearly half of No CAM users expressed that providers should be able to answer questions about CAM (Table 6) and that CAM therapies should be offered in the regular oncology settings (Table 7). The option to leave additional responses was used by 89 out of 198 CAM users: they addressed the importance of evidence (n = 42), competence and quality of CAM modalities that they thought should be included in oncological care, they suggested specific methods or indications, expressed the wish that providers should at least offer information on CAM modalities and specified a wish for treatment diversity.

Table 6 Should providers be able to inform?
Table 7 Should CAM be offered within conventional cancer care?

Discussion

This study describes CAM use and related experiences among Swedish patients with solid tumors in both curative and palliative stage. One third (34%) of participants had used CAM at some point in their life and 26% after cancer diagnosis. This is in line with previous studies, e.g. a European study where CAM use was reported by 36% [3], without distinction between use before or after cancer diagnosis. The similarity to our findings is surprising as access to and advice on CAM modalities are generally low within cancer care in Sweden, due to Swedish regulations requiring health personnel to practice in accordance with “science and experiential knowledge” [27, 28]. Since patients in this study visited an oncological department, CAM seems to be mainly used complementary and not alternatively to conventional therapy. This also corresponds to participants´ free-text responses where they specify reasons for and benefits from CAM use.

In line with international [3, 29, 30] and other Scandinavian surveys [4, 9], we found statistically significant relationships between CAM use and being female, younger and higher educated. These results may suggest high health literacy among CAM users and a gender aspect of unmet needs in conventional care.

In agreement with previous results [3, 31] we found that patients used and combined a diversity of CAM modalities. Natural products and mind-body therapies were most popular. This concurrent and multimodal use implies an immense challenge for research and practice in regard to interactions [32], efficacy and educational needs among patients as well as providers in a pluralistic context [33].

In our study, 5.6% of CAM users reported mild and transient adverse effects (mostly gastrointestinal discomfort) from a CAM modality, which was mainly related to intake of natural products, as shown earlier [3, 9, 34]. Participants’ detailed specifications related to their experiences of CAM use as well as previous results on patients´ concerns about risks for interactions [35] indicate that many CAM users pay close attention to both positive and negative consequences of their CAM use. Thus, patients seem to be a potential and possibly underestimated resource for monitoring of adverse effects and effectiveness, as also acknowledged by the introduction of PROM/PREM in evaluating clinical trials. Therefore, an open and trustful dialogue between patients and providers is fundamental. However, in our study only 2% of No CAM users and 33% of CAM users had discussed CAM modalities with their provider, i.e. less than in recent Scandinavian literature [9, 10, 34]. The results from these previous studies indicate that around 50% of patients have a dialogue about CAM. Consequently, up to 67% of CAM use in our study may be unknown to providers representing both potential risks and undiscovered possibilities. Since CAM users were more likely to have discussed CAM compared to No CAM users, this dialogue was usually patient initiated, suggesting a threat to patient safety. For example, it has been shown previously that physicians who are perceived to be poorly informed or negative about CAM induce safety concerns in terms of e.g. potential undiscovered interactions as well as patient anxiety [35].

Two thirds (67%) of CAM users and 49% of No CAM users (Table 6) thought that providers should have enough knowledge to be able to answer questions on CAM; which has been shown earlier [11, 35]. However, conventional health care was the least common source of information about CAM modalities while media, family or friends and internet were most commonly used; as previously reported [31, 34] and highlighting the need for quality assured information. Our findings are not surprising since Swedish health care professionals still report lack of knowledge about CAM [11, 21, 36,37,38]. Better knowledge is known to increase dialogue [21,22,23].

The main reasons for CAM use were to improve well-being and to increase the body’s ability to fight cancer, i.e. not to fight cancer per se. Benefits were reported as being mostly physical and emotional. Both reasons for use and perceived benefits were often multifaceted, e.g. a single CAM modality was used and perceived efficacious both for improving emotional well-being and reducing adverse effects of conventional treatment. Notably, fighting cancer was rarely given as a reason for CAM use. These results correspond to earlier research indicating complex motives for CAM use [39,40,41,42,43], shifting motives over time [34, 44] and benefits not always related to initial reasons for use [3, 8, 30]. Also, in line with previous findings, [3] patients in this study reported high satisfaction with CAM (87%) and the majority of users considered CAM being worth the money (91% of CAM users). Moreover, 71% of CAM users and 48% of No CAM users considered that CAM modalities should be offered within conventional cancer care and participants stressed the importance of scientific evidence, competence and quality of CAM. While patients’ satisfaction with care - conventional or CAM - is multifaceted and clearly needs to be considered together with other aspects of evidence, as also patients argue in their responses, the high satisfaction rates among CAM users found here needs to be considered by decision makers in cancer care.

Strengths of this study include the cross-sectional design with three different data collection sites and the large sample size. These factors help ensure representativity for cancer patients with solid tumors in urban Sweden, although the results may not be fully transferable to more rural areas. The questionnaires were completed anonymously, and responses could not be linked to electronic health records or sociodemographic variables; thus, participants’ diagnoses and socio-demographics are exclusively self-reported. Self-selection bias potentially attracting CAM users to participate to a larger extent than No CAM users is however unlikely since gender proportions were similar in visits to the clinic and responses to the questionnaire. If CAM users had been more likely to respond to the questionnaire, there would be an overrepresentation of women among responders since female patients represented 80% of CAM users in our material.

Strengths with the questionnaire, although not formally validated, were that an earlier version had been previously used in a large European survey, and that space was given for additional free-text responses. The recruitment of participants at their follow-up visit at the oncology department might explain somewhat lower CAM use compared with previous studies. Terminally ill patients were not represented and in general, participants might have been reluctant to admit CAM use while waiting for conventional oncological care. The response rate of 58% could be seen as a limitation of the study and a higher response rate would have been desirable, however, it is in line with previously published CAM surveys [45].

Conclusion

To conclude, the results here suggest that at least one fourth of Swedish cancer patients use CAM, are highly satisfied with this use, generally have reasonable expectations and are alert to the consequences. Therefore, our results point to an urgency of research on CAM and an informed professional practice to ensure patient safety and satisfaction. Cancer care professionals need to be able to discuss CAM based on the three principles of evidence-based medicine (patients’ values, professional experience, current research). Swedish cancer care needs a strategy for research and education about CAM to integrate CAM modalities with shown beneficial value for patients and to avoid possibly harmful CAM. The concept of integrative oncology [14] may provide a professional solution both regarding providers´ and patients’ needs.

Abbreviations

CAM:

Complementary and Alternative Medicine

Q:

Question

References

  1. 1.

    Complementary, Alternative or Integrative Health: What’s In a Name? https://nccih.nih.gov/health/integrative-health. Accessed 9 January 2019.

  2. 2.

    Horneber M, Bueschel G, Dennert G, Less D, Ritter E, Zwahlen M. How many cancer patients use complementary and alternative medicine: a systematic review and metaanalysis. Integr Cancer Ther. 2012;11(3):187–203.

  3. 3.

    Molassiotis A, Fernadez-Ortega P, Pud D, Ozden G, Scott JA, Panteli V, Margulies A, Browall M, Magri M, Selvekerova S, et al. Use of complementary and alternative medicine in cancer patients: a European survey. Ann Oncol. 2005;16(4):655–63.

  4. 4.

    Kristoffersen AE, Norheim AJ. M. V: complementary and alternative medicine use among Norwegian Cancer survivors: gender-specific prevalence and associations for use. Evid Based Complement Alternat Med. 2013;10.

  5. 5.

    Abrams DI, Weil AT. Integrative oncology. 2nd ed. New York: Oxford University Press; 2014.

  6. 6.

    Greenlee H, DuPont-Reyes MJ, Balneaves LG, Carlson LE, Cohen MR, Deng G, Johnson JA, Mumber M, Seely D, Zick SM, et al. Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment. CA Cancer J Clin. 2017;67(3):194–232.

  7. 7.

    Lyman GH, Greenlee H, Bohlke K, Bao T, DeMichele AM, Deng GE, Fouladbakhsh JM, Gil B, Hershman DL, Mansfield S, Mussallem DM, Mustian KM, Price E, Rafte S, Cohen L. Integrative Therapies During and After Breast Cancer Treatment: ASCO Endorsement of the SIO Clinical Practice Guideline. Journal of Clinical Oncology 2018;36(25):2647–2655

  8. 8.

    Stub T, Quandt SA, Arcury TA, Sandberg JC, Kristoffersen AE, Musial F, Salamonsen A. Perception of risk and communication among conventional and complementary health care providers involving cancer patients' use of complementary therapies: a literature review. BMC Complement Altern Med. 2016;16:353.

  9. 9.

    Nissen N, Lunde A, Pedersen CG, Johannessen H. The use of complementary and alternative medicine after the completion of hospital treatment for colorectal cancer: findings from a questionnaire study in Denmark. BMC Complement Altern Med. 2014;14:388.

  10. 10.

    Lovgren M, Wilde-Larsson B, Hok J, Levealahti H, Tishelman C. Push or pull? Relationships between lung cancer patients' perceptions of quality of care and use of complementary and alternative medicine. European journal of oncology nursing : the official journal of European Oncology Nursing Society. 2011;15(4):311–7.

  11. 11.

    King N, Balneaves LG, Levin GT, Nguyen T, Nation JG, Card C, Truant T, Carlson LE. Surveys of Cancer patients and Cancer health care providers regarding complementary therapy use, communication, and information needs. Integr Cancer Ther. 2015;14(6):515–24.

  12. 12.

    Juraskova I, Hegedus L, Butow P, Smith A, Schofield P. Discussing complementary therapy use with early-stage breast cancer patients: exploring the communication gap. Integr Cancer Ther. 2010;9(2):168–76.

  13. 13.

    Yun H, Sun L, Mao JJ. Growth of Integrative Medicine at Leading Cancer Centers Between 2009 and 2016: A Systematic Analysis of NCI-Designated Comprehensive Cancer Center Websites. JNCI Monographs 2017;2017(52).

  14. 14.

    Witt CM, Balneaves LG, Cardoso MJ, Cohen L, Greenlee H, Johnstone P, Kucuk O, Mailman J, Mao JJ. A comprehensive definition for integrative oncology. J Natl Cancer Inst Monogr. 2017;(52).

  15. 15.

    Memorial Sloan Kettering Cancer Center Integrative Medicine. https://www.mskcc.org/cancer-care/diagnosis-treatment/symptom-management/integrative-medicine. Accessed 9 Jan 2019.

  16. 16.

    Osher Center for Integrative Medicine http://oshercenter.org/clinical/. Accessed 9 Jan 2019.

  17. 17.

    MD Anderson Integrative Medicine Center. https://www.mdanderson.org/patients-family/diagnosis-treatment/care-centers-clinics/integrative-medicine-center.html. Accessed 9 Jan 2019.

  18. 18.

    Balneaves LG, Truant TL, Verhoef MJ, Ross B, Porcino AJ, Wong M, Brazier AS. The complementary medicine education and outcomes (CAMEO) program: a foundation for patient and health professional education and decision support programs. Patient Educ Couns. 2012;89(3):461–6.

  19. 19.

    Nasjonalt forskningssenter innen komplemenaer og alternativ medisin. http://nafkam.no/. Accessed 9 Jan 2019.

  20. 20.

    Hietala M, Henningson M, Ingvar C, Jonsson PE, Rose C, Jernstrom H. Natural remedy use in a prospective cohort of breast cancer patients in southern Sweden. Acta Oncol. 2011;50(1):134–43.

  21. 21.

    Bjersa K, Stener Victorin E, Fagevik Olsen M. Knowledge about complementary, alternative and integrative medicine (CAM) among registered health care providers in Swedish surgical care: a national survey among university hospitals. BMC Complement Altern Med. 2012;12:42.

  22. 22.

    Jong M, Lundqvist V, Jong MC. A cross-sectional study on Swedish licensed nurses' use, practice, perception and knowledge about complementary and alternative medicine. Scand J Caring Sci. 2015;29(4):642–50.

  23. 23.

    Bjersa K, Forsberg A, Fagevik Olsen M. Perceptions of complementary therapies among Swedish registered professions in surgical care. Complement Ther Clin Pract. 2011;17(1):44–9.

  24. 24.

    Sackett DL, Straus SE, Richarson WS, Rosenberg W, Haynes RB. Evidence-based medicine: how to practice and teach EBM. 2nd ed. Edinburgh: Elsevier Churchill Livingstone; 2000.

  25. 25.

    Graneheim UH, Lundman B. Qualitative content analysis in nursing research: concepts, procedures and measures to achieve trustworthiness. Nurse Educ Today. 2004;24(2):105–12.

  26. 26.

    Patton MQ: Qualitative Research & Evaluation Methods. Integrating Theory and Practice, 4 Revised edition edn: SAGE Publications Inc; 2015.

  27. 27.

    Knox KE, Fonnebo V, Falkenberg T. Emerging complementary and alternative medicine policy initiatives and the need for dialogue. J Altern Complement Med. 2009;15(9):959–62.

  28. 28.

    Patientsäkerhetslag (2010:659). https://www.riksdagen.se/sv/dokument-lagar/dokument/svensk-forfattningssamling/patientsakerhetslag-2010659_sfs-2010-659. Accessed 9 Jan 2019.

  29. 29.

    Verhoef MJ, Balneaves LG, Boon HS, Vroegindewey A. Reasons for and characteristics associated with complementary and alternative medicine use among adult cancer patients: a systematic review. Integr Cancer Ther. 2005;4(4):274–86.

  30. 30.

    Patterson RE, Neuhouser ML, Hedderson MM, Schwartz SM, Standish LJ, Bowen DJ, Marshall LM. Types of alternative medicine used by patients with breast, colon, or prostate cancer: predictors, motives, and costs. J Altern Complement Med. 2002;8(4):477–85.

  31. 31.

    Wanchai A, Armer JM, Stewart BR. Complementary and alternative medicine use among women with breast cancer: a systematic review. Clin J Oncol Nurs. 2010;14(4):E45–55.

  32. 32.

    Alsanad SM, Howard RL, Williamson EM. An assessment of the impact of herb-drug combinations used by cancer patients. BMC Complement Altern Med. 2016;16(1):393.

  33. 33.

    Kiene H, Brinkhaus B, Fischer G, Girke M, Hahn EG, Hoppe HD, Jütte R, Kraft K, Klitzsch W, Matthiessen PF, et al. Professional treatment in the context of medical pluralism—a German perspective. European Journal of Integrative Medicine. 2010;2(2):53–6.

  34. 34.

    Engdal S, Steinsbekk A, Klepp O, Nilsen OG. Herbal use among cancer patients during palliative or curative chemotherapy treatment in Norway. Support Care Cancer. 2008;16(7):763–9.

  35. 35.

    Smithson J, Paterson C, Britten N, Evans M, Lewith G. Cancer patients' experiences of using complementary therapies: polarization and integration. J Health Serv Res Policy. 2010;15(Suppl 2):54–61.

  36. 36.

    Salomonsen LJ, Skovgaard L, la Cour S, Nyborg L, Launso L, Fonnebo V. Use of complementary and alternative medicine at Norwegian and Danish hospitals. BMC Complement Altern Med. 2011;11:4.

  37. 37.

    Risberg T, Kolstad A, Bremnes Y, Holte H, Wist EA, Mella O, Klepp O, Wilsgaard T, Cassileth BR. Knowledge of and attitudes toward complementary and alternative therapies. a national multicentre study of oncology professionals in Norway Eur J Cancer. 2004;40(4):529–35.

  38. 38.

    Kolstad A, Risberg T, Bremnes Y, Wilsgaard T, Holte H, Klepp O, Mella O, Wist E. Use of complementary and alternative therapies: a national multicentre study of oncology health professionals in Norway. Support Care Cancer. 2004;12(5):312–8.

  39. 39.

    Cassileth BR, Lusk EJ, Strouse TB, Bodenheimer BJ. Contemporary unorthodox treatments in cancer medicine. A study of patients, treatments, and practitioners. Ann Intern Med. 1984;101(1):105–12.

  40. 40.

    Sollner W, Maislinger S, DeVries A, Steixner E, Rumpold G, Lukas P. Use of complementary and alternative medicine by cancer patients is not associated with perceived distress or poor compliance with standard treatment but with active coping behavior: a survey. Cancer. 2000;89(4):873–80.

  41. 41.

    Hök J. Use of complementary and alternative medicine in the context of cancer. Perspective on exceptional experiences. Stockholm: Karolinska Institutet; 2009.

  42. 42.

    Smithson J, Britten N, Paterson C, Lewith G, Evans M. The experience of using complementary therapies after a diagnosis of cancer: a qualitative synthesis. Health (London). 2012;16(1):19–39.

  43. 43.

    Risberg T, Vickers A, Bremnes RM, Wist EA, Kaasa S, Cassileth BR. Does use of alternative medicine predict survival from cancer? Eur J Cancer. 2003;39(3):372–7.

  44. 44.

    Danell JA. From disappointment to holistic ideals: a qualitative study on motives and experiences of using complementary and alternative medicine in Sweden. J Public Health Res. 2015;4(2):538.

  45. 45.

    Nilsson J, Kallman M, Ostlund U, Holgersson G, Bergqvist M, Bergstrom S. The use of complementary and alternative medicine in Scandinavia. Anticancer Res. 2016;36(7):3243–51.

Download references

Acknowledgements

We thank all patients and staff involved at the Department of Oncology at Karolinska University Hospital and Regional Cancer Center Stockholm/Gotland for providing administrative and technical support (M. Franchell and V. Rodriguez-Ruiz) and research time for conducting this study. Special thanks to A. Molassiotis for sharing the original questionnaire.

Funding

This research was supported by the Regional Cancer Centre Stockholm Gotland (Grant 2013) covering costs of ethical approval, data collection, analysis and report writing.

Availability of data and materials

The datasets generated and analyzed during the current study are not publicly available due to the risk to compromise anonymity. An adapted version is available from the corresponding author on reasonable request.

Authors' contributions

K.W. and J.H.N.: study concept, study design; data acquisition, quality control of data, data analysis and interpretation; manuscript preparation, editing and review. A.S.: quality control of data and algorithms, data analysis and interpretation, statistical analysis; manuscript preparation and review. L.S. and R.H.: study concept, study design; manuscript preparation and review. All authors have read and approved the manuscript.

Author information

Correspondence to Kathrin Wode.

Ethics declarations

Ethics approval and consent to participate

The study was approved by the Regional Ethical Review Board in Stockholm (Dnr. 2014/814–31/5). Since participation was anonymous, informed consent was given with the completion of the questionnaire, in accordance with the approved ethics.

Consent for publication

Participants agreed to publication of results.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Additional file

Additional file 1:

Questionnaire_eng_Wode et al_190128.pdf; English translation of used Swedish questionnaire. Description of data: Questionnaire containing 19 questions. (PDF 313 kb)

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Wode, K., Henriksson, R., Sharp, L. et al. Cancer patients’ use of complementary and alternative medicine in Sweden: a cross-sectional study. BMC Complement Altern Med 19, 62 (2019) doi:10.1186/s12906-019-2452-5

Download citation

Keywords

  • Complementary and alternative medicine/utilization
  • Oncology
  • Cross-sectional studies
  • Cancer
  • Adult
  • Integrative oncology
  • Sweden
  • Europe
  • Epidemiology
  • Evidence-based medicine